BAKER BROS. ADVISORS LP
Q1 2022 13F-HR Holdings
Net value change ($000)
-3,150,130
(-15.3%)
New positions
2
Sold out positions
3
Turnover %
0.1%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| INCY | 403,760 | 16.4% |
| ACAD | 36,881 | 3.8% |
| BCRX | 30,633 | 17.4% |
| Horizon Therapeutics Public Ltd Co | 30,007 | 46.5% |
| MDGL | 20,060 | 15.8% |
| Global Blood Therapeutics, Inc. | 17,800 | 18.3% |
| JBIO | 16,346 | 75.7% |
| 2seventy bio, Inc. | 13,834 | 64.8% |
| REPL | 11,286 | 70.2% |
| RYTM | 8,966 | 23.3% |
Top Reduces (Value $000, Stocks/ETFs)
| KOD | -1,121,693 | -90.1% |
| ONC | -960,700 | -30.4% |
| Seagen Inc. | -492,002 | -6.8% |
| Mirati Therapeutics, Inc. | -90,889 | -43.9% |
| BMRN | -85,731 | -12.7% |
| ASND | -77,979 | -12.8% |
| Invitae Corp | -72,076 | -47.8% |
| PACB | -61,855 | -55.5% |
| PRLD | -56,188 | -44.6% |
| KYMR | -50,485 | -33.3% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|